Journal profile · Ophthalmology
Journal of Ocular Pharmacology and Therapeutics
ISSN 1080-7683 · eISSN 1557-7732 · Mary Ann Liebert Inc. · UNITED STATES · Quarterly · Founded 1995
Journal of Ocular Pharmacology and Therapeutics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.18; hybrid open access; review about 1 month (community reports); community-reported acceptance: about 5%; 92 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Ocular Pharmacology and Therapeutics is published by Mary Ann Liebert Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Glaucoma and retinal disorders, Retinal Diseases and Treatments and Ocular Surface and Contact Lens, together about 43.2% of its articles. Its main subfields are Ophthalmology and Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.
Source: LetPub
Research area (LetPub): Ophthalmology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Glaucoma and retinal disordersMedicine17.5%
- Retinal Diseases and TreatmentsMedicine13.1%
- Ocular Surface and Contact LensMedicine12.7%
- Ocular Infections and TreatmentsMedicine6.8%
- Corneal Surgery and TreatmentsMedicine5.9%
- Ocular Diseases and Behçet’s SyndromeMedicine4.9%
- Corneal surgery and disordersMedicine4.9%
- Retinal and Macular SurgeryMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Ophthalmology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Ophthalmology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Ophthalmology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.18LetPub ·
- CiteScore 2026-06
- 4.7LetPub ·
- SJR 2026-06
- 0.62LetPub ·
- SNIP 2026-06
- 0.85LetPub ·
- h-index
- 53LetPub ·
- h-index
- 89OpenAlex ·
- i10-index
- 1,738OpenAlex ·
- 2-year mean citedness
- 1.67OpenAlex ·
- Self-citation rate
- 4.5%LetPub ·
- Share of gold OA articles
- 11.32%LetPub ·
Volume
- Articles per year
- 76LetPub ·
Articles by year OpenAlex count · 3,091 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 76 | 9 | 13 |
| 2025 | 92 | 19 | 123 |
| 2024 | 83 | 17 | 282 |
| 2023 | 90 | 22 | 545 |
| 2022 | 78 | 26 | 672 |
| 2021 | 86 | 19 | 866 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 5%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Mary Ann Liebert Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1995
- ISSN
- 1080-7683
- Electronic ISSN
- 1557-7732
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Journal of Ocular Pharmacology and Therapeutics
What CAS zone is Journal of Ocular Pharmacology and Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Ocular Pharmacology and Therapeutics is in Zone 4 of Medicine, and in Zone 3 of the minor category Ophthalmology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Ocular Pharmacology and Therapeutics?
The latest impact factor listed by LetPub is 2.18; CiteScore 4.7, h-index 89.
How long does peer review take at Journal of Ocular Pharmacology and Therapeutics?
Authors report an average review time of about 1 month; the community-reported acceptance is “about 5%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Journal of Ocular Pharmacology and Therapeutics?
According to LetPub and DOAJ records, Journal of Ocular Pharmacology and Therapeutics is indexed in SCIE and Scopus.
Is Journal of Ocular Pharmacology and Therapeutics open access, and what is the APC?
Journal of Ocular Pharmacology and Therapeutics is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .